

PAXMAN receives order for 10 scalp cooling systems for the Italian market.

Paxman's global partner for Italy, Praesidia s.r.l., has placed an order for 10 PSCS2 model Paxman Scalp Cooling systems to fulfil demand for scalp cooling from Institute G. Pascale in Naples.

The hospital will be a brand new user of Paxman Scalp Cooling and the 10 devices, which each treat 2 patients simultaneously, will allow their clinical teams to offer the option of scalp cooling to all appropriate cancer patients.

The rate of cancer for both men and women in Italy is an estimated 290.6 per 100,000 of population and the country has the highest survival rates for several types of cancer five years after diagnosis than in the rest of the European Union on average.

Since joining Paxman's network of global partners in 2011 Praesidia have installed 91 Paxman scalp cooling systems in hospital cancer centres throughout Italy.

Contacts

Richard Paxman, CEO Tel: +44 7968 020641

Email: richard@paxmanscalpcooling.com

www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

PAXMAN receives order for 10 scalp cooling systems for the Italian market.